Loading...
Back to narrative

INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance

Digital Transformation And AI Adoption Will Expand Pharma Market

INDGN logo
INDGN
AnalystConsensusTarget
Not Invested
Published 11 May 2025

Update shared on 10 Nov 2025

Fair value Decreased 5.44%
Next
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-9.5%
7D
1.0%

Narrative Update on Indegene Price Target

Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics.

What's in the News

  • Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025. The meeting will also consider ESOP and RSU allotments (Board Meeting).
  • The expansion of the Consulting Practice aims to help life sciences organizations with complex and large-scale transformations by combining strategy, implementation expertise, and measurable outcomes (Business Expansions).
  • A strategic partnership has been announced between Indegene and Datavant to improve patient recruitment in clinical trials, especially for rare diseases, by integrating advanced data enrichment into Indegene's recruitment platform (Strategic Alliances).
  • A new center has opened in Pune, India, expanding Indegene's operational capacity and leveraging local talent to better serve global pharma, biotech, and medical device clients (Business Expansions).

Valuation Changes

  • The consensus analyst price target has decreased from ₹644.67 to ₹609.57, reflecting a lower expected fair value for the company.
  • The discount rate has risen slightly from 13.33% to 14.01%, indicating increased perceived risk or cost of capital.
  • The revenue growth projection has increased significantly from 11.95% to 16.90%, suggesting higher anticipated topline expansion.
  • The net profit margin expectation has dropped from 15.75% to 12.78%, pointing to slimmer projected profitability.
  • The future P/E remains stable, moving marginally from 35.16x to 35.22x, implying minimal change in valuation multiples.

Have other thoughts on Indegene?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.